Press Releases

First Data Derived from ABCD Worldwide EndoBarrier Registry Presented at ADA Shows Sustained Metabolic Improvements in Patients with Obesity and Type 2 Diabetes at Six Months Post-explant

BOSTON and SYDNEY – 12 June 2017 – GI Dynamics®, Inc., (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe for patients with type 2 diabetes and obesity, today announced data from a UK National Health Service (NHS) EndoBarrier Registry presented at the American Diabetes Association’s 77th Scientific Sessions demonstrated that metabolic improvements made by patients while implanted with EndoBarrier were sustained six months after EndoBarrier was explanted.

read more

GI Dynamics Announces Change to Board of Directors

BOSTON and SYDNEY — 2 June 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has developed an innovative device to improve outcomes for patients diagnosed with type 2 diabetes and obesity, announces today that the board of directors has received the resignation of GI Dynamics...

read more

GI Dynamics Announces EndoBarrier CE Mark Suspension

BOSTON and SYDNEY — 18 May 2017 — GI Dynamics®, Inc. (ASX:GID) today announced that it received notification from its notified body SGS United Kingdom Limited (SGS) that the CE Mark for its EndoBarrier® system has been suspended pending closure of nonconformances related to its quality management...

read more

GI Dynamics Selects Allenby Capital to Explore AIM Listing Option

BOSTON and SYDNEY — 3 May 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces Allenby Capital Limited’s engagement to explore options for seeking...

read more
Page 2 of 1812345...10...Last »